Re-Thinking Clinical Trials in Oncology
 Assessing the landscape of novel trial design for cancer therapies to improve data collection, enhance patient access, and drive clinical outcomes for breakthrough therapies

October 28, 2020 | Live Virtual Forum (EST)

Amy Abernethy MD, PhD

Principal Deputy Commissioner, Acting CIO US Food & Drug Administration (FDA)

Amy P. Abernethy, M.D., Ph.D. is an oncologist and internationally recognized clinical data expert and clinical researcher. As the Principal Deputy Commissioner of Food and Drugs, Dr. Abernethy helps oversee FDA’s day-to-day functioning and directs special and high-priority cross-cutting initiatives that impact the regulation of drugs, medical devices, tobacco and food. As acting Chief Information Officer, she oversees FDA’s data and technical vision, and its execution. She has held multiple executive roles at Flatiron Health and was professor of medicine at Duke University School of Medicine, where she ran the Center for Learning Health Care and the Duke Cancer Care Research Program. Dr. Abernethy received her M.D. at Duke University, where she did her internal medicine residency, served as chief resident, and completed her hematology/oncology fellowship. She received her Ph.D. from Flinders University, her B.A. from the University of Pennsylvania and is boarded in palliative medicine.

WEDNESDAY, OCTOBER 28

2:00 PM Keynote Fireside Chat: The Impact of “Big Data” and Data Analytics on Trial Design and Execution

Discuss the importance of developing more efficient ways to collect and utilize data to enhance the development of new treatments and cures. Hear an agency perspective on efforts to not only modernize its technological infrastructure but also invest in expertise and build initiatives that support and evaluate the work being done on the forefront of science and technology to improve clinical outcomes for cancer patients.